This clinical trial is focused on studying the effects of a treatment called inebilizumab on a condition known as myasthenia gravis. Myasthenia gravis is a disease that causes weakness in the muscles, and it can be due to specific antibodies, which are proteins in the body that mistakenly attack healthy cells. These antibodies are called acetylcholine receptor antibodies (AChR) or muscle-specific kinase antibodies (MuSK). The treatment being tested, inebilizumab, is given as an injection into a vein, and it is being studied to see if it can help reduce the disability caused by myasthenia gravis.

The study is designed to compare the effects of inebilizumab with a placebo, which is a substance with no active medication. Participants in the study will receive either inebilizumab or the placebo. The study will last for a period of time, during which participants will receive regular doses of the treatment. The goal is to observe any changes in the participants’ ability to perform daily activities and to assess the overall safety and effectiveness of inebilizumab.

Throughout the study, participants will be monitored for any side effects or changes in their condition. The study will also look at how inebilizumab affects the use of other medications, such as corticosteroids, which are often used to manage myasthenia gravis. By the end of the study, researchers hope to determine if inebilizumab can provide a meaningful improvement in the lives of those living with myasthenia gravis.